Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421

BACKGROUND: Phase II trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate specific antigen (PSA) changes to assess activity. Given the increasing detection of measurable disease, RECIST changes warrant consideration to evaluat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Genitourin Cancer
Auteurs principaux: Sonpavde, Guru, Pond, Gregory R., Plets, Melissa, Tangen, Catherine M., Hussain, Maha H.A., Lara, Primo N., Goldkorn, Amir, Garzotto, Mark G., Mack, Philip C., Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M., Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Quinn, David I.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734863/
https://ncbi.nlm.nih.gov/pubmed/28579151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.05.014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires